Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents

Global tuberculosis report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. Mitchison, 2005, The diagnosis and therapy of tuberculosis during the past 100 years, Am. J. Respir. Crit. Care Med., 171, 699, 10.1164/rccm.200411-1603OE Russell, 2010, Tuberculosis: what we don't know can, and does, hurt us, Science, 328, 852, 10.1126/science.1184784 Campaniço, 2018, Drug discovery in tuberculosis. New drug targets and antimycobacterial agents, Eur. J. Med. Chem., 150, 10.1016/j.ejmech.2018.03.020 Singh Bais, 2018, Investigating the inhibitory potential of 2-Aminopurine metal complexes against serine/threonine protein kinases from Mycobacterium tuberculosis, Tuberculosis, 108, 47, 10.1016/j.tube.2017.10.005 Meneghetti, 2016, Iron acquisition pathways as targets for antitubercular drugs, Curr. Med. Chem., 23, 4009, 10.2174/0929867323666160607223747 Fanzani, 2015, Mycobacterium tuberculosis low molecular weight phosphatases (MPtpA and MPtpB): from biological insight to inhibitors, Curr. Med. Chem., 22, 3110, 10.2174/0929867322666150812150036 Singh, 2017, Down-regulation of malate synthase in Mycobacterium tuberculosis H37Ra leads to reduced stress tolerance, persistence and survival in macrophages, Tuberculosis, 106, 73, 10.1016/j.tube.2017.07.006 Borisov, 2017, Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study, Eur. Respir. J., 49, 1700387, 10.1183/13993003.00387-2017 Zumla, 2013, Advances in the development of new tuberculosis drugs and treatment regimens, Nat. Rev. Drug Discov., 12, 388, 10.1038/nrd4001 Raymond, 2003, Enterobactin: an archetype for microbial iron transport, Proc. Natl. Acad. Sci. U. S. A, 100, 3584, 10.1073/pnas.0630018100 De Voss, 2000, The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages, Proc. Natl. Acad. Sci. U. S. A, 97, 1252, 10.1073/pnas.97.3.1252 Zwahlen, 2007, Structure and mechanism of MbtI, the salicylate synthase from Mycobacterium tuberculosis, Biochemistry, 46, 954, 10.1021/bi060852x Manos-Turvey, 2010, Inhibition studies of Mycobacterium tuberculosis salicylate synthase (MbtI), ChemMedChem, 5, 1067, 10.1002/cmdc.201000137 Manos-Turvey, 2012, Synthesis and evaluation of M. tuberculosis salicylate synthase (MbtI) inhibitors designed to probe plasticity in the active site, Org. Biomol. Chem., 10, 9223, 10.1039/c2ob26736e Harrison, 2006, The structure of MbtI from Mycobacterium tuberculosis, the first enzyme in the biosynthesis of the siderophore mycobactin, reveals it to be a salicylate synthase, J. Bacteriol., 188, 6081, 10.1128/JB.00338-06 Chi, 2012, Implications of binding mode and active site flexibility for inhibitor potency against the salicylate synthase from Mycobacterium tuberculosis, Biochemistry, 51, 4868, 10.1021/bi3002067 Wolber, 2005, LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters, J. Chem. Inf. Model., 45, 160, 10.1021/ci049885e Tuccinardi, 2014, Extensive consensus docking evaluation for ligand pose prediction and virtual screening studies, J. Chem. Inf. Model., 54, 2980, 10.1021/ci500424n Poli, 2016, Reliability analysis and optimization of the consensus docking approach for the development of virtual screening studies, J. Enzym. Inhib. Med. Chem., 31, 167, 10.1080/14756366.2016.1193736 Poli, 2015, Application of a FLAP-consensus docking mixed strategy for the identification of new fatty acid amide hydrolase inhibitors, J. Chem. Inf. Model., 55, 667, 10.1021/ci5006806 Granchi, 2015, Development and validation of a docking-based virtual screening platform for the identification of new lactate dehydrogenase inhibitors, Molecules, 20, 8772, 10.3390/molecules20058772 Tuccinardi, 2014, Identification and characterization of a new reversible MAGL inhibitor, Bioorg. Med. Chem., 22, 3285, 10.1016/j.bmc.2014.04.057 Vasan, 2010, Inhibitors of the salicylate synthase (MbtI) from Mycobacterium tuberculosis discovered by high-throughput screening, ChemMedChem, 5, 2079, 10.1002/cmdc.201000275 Bissantz, 2010, A medicinal chemist's guide to molecular interactions, J. Med. Chem., 53, 5061, 10.1021/jm100112j Brosch, 1999, Genomic analysis reveals variation between Mycobacterium tuberculosis H37Rv and the attenuated M. tuberculosis H37Ra strain, Infect. Immun., 67, 5678, 10.1128/IAI.67.11.5768-5774.1999 Sritharan, 2016, Iron homeostasis in Mycobacterium tuberculosis: mechanistic insight into siderophore-mediated iron uptake, J. Bacteriol., 198, 2399, 10.1128/JB.00359-16 Schwyn, 1987, Universal chemical assay for the detection and determination of siderophores, Anal. Biochem., 160, 47, 10.1016/0003-2697(87)90612-9 Porta, 2017, A field-based disparity analysis of new 1,2,5-oxadiazole derivatives endowed with antiproliferative activity, Chem. Biol. Drug Des., 90, 820, 10.1111/cbdd.13003 Korb, 2010, pharmACOphore: multiple flexible ligand alignment based on ant colony optimization, J. Chem. Inf. Model., 50, 1669, 10.1021/ci1000218 Korb, 2009, Empirical scoring functions for advanced protein-ligand docking with PLANTS, J. Chem. Inf. Model., 49, 84, 10.1021/ci800298z Case, 2015 Kerbarh, 2006, Crystal structures of Yersinia enterocolitica salicylate synthase and its complex with the reaction products salicylate and pyruvate, J. Mol. Biol., 357, 524, 10.1016/j.jmb.2005.12.078 Yu, 2011, Role of Mg2+ ions in protein kinase phosphorylation: insights from molecular dynamics simulations of ATP-kinase complexes, Mol. Simulat., 37, 1143, 10.1080/08927022.2011.561430 Casalino, 2016, Structural, dynamical and catalytic interplay between Mg2+ ions and RNA. Vices and virtues of atomistic simulations, Inorg. Chim. Acta., 452, 73, 10.1016/j.ica.2016.02.011 Casalino, 2017, Development of site-specific Mg2+-RNA force field parameters: a dream or reality? Guidelines from combined molecular dynamics and quantum mechanics simulations, J. Chem. Theor. Comput., 13, 340, 10.1021/acs.jctc.6b00905 Hayatshahi, 2017, Computational assessment of potassium and magnesium ion binding to a buried pocket in GT pase-associating center RNA, J. Phys. Chem. B, 121, 451, 10.1021/acs.jpcb.6b08764 Li, 2013, Rational design of particle mesh ewald compatible Lennard-Jones parameters for +2 metal cations in explicit solvent, J. Chem. Theor. Comput., 9, 2733, 10.1021/ct400146w York, 1993, The effect of long-range electrostatic interactions in simulations of macromolecular crystals: a comparison of the Ewald and truncated list methods, J. Chem. Phys., 99, 8345, 10.1063/1.465608 Grisostomi, 1997, Efficient in vivo synthesis and rapid purification of chorismic acid using an engineered Escherichia coli strain, Bioorg. Chem., 25, 297, 10.1006/bioo.1997.1073 Jasial, 2017, How frequently are pan-assay interference compounds active? Large-scale analysis of screening data reveals diverse activity profiles, low global hit frequency, and many consistently inactive compounds, J. Med. Chem., 60, 3879, 10.1021/acs.jmedchem.7b00154 Baell, 2010, New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays, J. Med. Chem., 53, 2719, 10.1021/jm901137j Shoichet, 2006, Screening in a spirit haunted world, Drug Discov. Today, 11, 607, 10.1016/j.drudis.2006.05.014 Dahlin, 2015, PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS, J. Med. Chem., 58, 2091, 10.1021/jm5019093 Siegrist, 2009, Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition, Proc. Natl. Acad. Sci. U. S. A, 106, 18792, 10.1073/pnas.0900589106 Reddy, 2013, Disruption of mycobactin biosynthesis leads to attenuation of Mycobacterium tuberculosis for growth and virulence, J. Infect. Dis., 208, 1255, 10.1093/infdis/jit250